Schwarz Dygos Wheeler Investment Advisors LLC Decreases Position in CVS Health Co. (NYSE:CVS)

Schwarz Dygos Wheeler Investment Advisors LLC reduced its stake in CVS Health Co. (NYSE:CVS) by 52.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,708 shares of the pharmacy operator’s stock after selling 10,851 shares during the period. Schwarz Dygos Wheeler Investment Advisors LLC’s holdings in CVS Health were worth $436,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of CVS. CWA Asset Management Group LLC acquired a new position in CVS Health in the third quarter valued at $777,000. SpiderRock Advisors LLC boosted its position in shares of CVS Health by 3.2% in the 3rd quarter. SpiderRock Advisors LLC now owns 10,807 shares of the pharmacy operator’s stock valued at $680,000 after purchasing an additional 332 shares during the period. Assetmark Inc. increased its position in CVS Health by 9.7% during the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock worth $25,781,000 after buying an additional 36,132 shares during the period. Lindbrook Capital LLC lifted its stake in CVS Health by 8.8% in the third quarter. Lindbrook Capital LLC now owns 6,524 shares of the pharmacy operator’s stock valued at $410,000 after buying an additional 527 shares during the last quarter. Finally, Tyler Stone Wealth Management boosted its holdings in shares of CVS Health by 83.7% in the third quarter. Tyler Stone Wealth Management now owns 10,169 shares of the pharmacy operator’s stock valued at $639,000 after acquiring an additional 4,632 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE:CVS opened at $66.34 on Monday. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The firm has a market capitalization of $83.64 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The business’s 50 day simple moving average is $56.42 and its 200-day simple moving average is $56.73. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.01%. The ex-dividend date was Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 72.68%.

Wall Street Analyst Weigh In

Several research firms recently commented on CVS. UBS Group reduced their price target on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research report on Tuesday, February 11th. Evercore ISI upped their target price on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 12th. Barclays increased their price objective on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $69.83.

Insider Activity

In related news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.